Zobrazeno 241 - 250
of 1 548
pro vyhledávání: ''
Autor:
Danny R. Welch, Lanjing Wei, Xiaoqing Wu, Liang Xu, Cuncong Zhong, Gulhumay Gardashova, Dan A. Dixon, Jeffrey Aubé, Qi Zhang, Lan Lan
Publikováno v:
Cancer Research. 80:P5-05
Triple negative breast cancer (TNBC) has a lower 5-year survival rate and higher recurrence rate compared to other types of breast cancer, which is partially due to the acquired resistance to current treatment regimens. The RNA-binding protein Hu ant
Autor:
Ming-Yang Wang, Kien Thiam Tan, An Hsu, Ming-Shen Dai, Dwang-Ying Chang, Yen-Shen Lu, De-Wei Zhuo, Shu-Han Chang, Ling-Yi Huang, Ching-Hung Lin, I-Chun Chen, Tom Wei-Wu Chen, Ann-Lii Cheng, Yen-Jung Lu
Publikováno v:
Cancer Research. 80:P5-01
Background: With more hormonal therapies (HT) based treatment (tx) available, predictive markers that could lead to a selection of the optimal tx is necessary. The predictive role of ctDNA mutations in ER+/HER2- MBC after prior HT is less well charac
Autor:
Howard C. Crawford, Marina Pasca di Magliano, Joyce K. Thompson, Filip Bednar, Osama Alkhalili, Emily Wu
Publikováno v:
Cancer Research. 79:C56-C56
Rare acinar cells expressing Bmi1, a component of the Polycomb Repressor Complex 1 (PRC1), represent a reservoir of cells contributing to pancreatic repair during injury and stress. This is marked by acinar-ductal metaplasia (ADM), a transition of ac
Autor:
Izhak Haviv, Lana Kupershmidt, Evgeny Solomonov, Salomon M. Stemmer, Neta Moskovits, Hadas Reuveni
Publikováno v:
Cancer Research. 79:C45-C45
Background: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwide, with poor outcome of current treatments. Major contributors to therapeutic resistance in PDAC include Kras mutations, a dense desmoplas
Autor:
Sophia S. Schuman, Kajsa E. Affolter, Mark R. Silvis, Dilru Silva, Conan Kinsey, Martin McMahon
Publikováno v:
Cancer Research. 79:C30-C30
Pancreatic ductal adenocarcinoma (PDAC) is a recalcitrant disease responsible for ~43,000 deaths in the USA in 2017. Despite an advanced understanding of the genetics, biochemistry, and biology of pancreatic cancer, there is no effective pathway-targ
Publikováno v:
Molecular Cancer Therapeutics. 18:C084-C084
ROS1 rearrangement was observed in about 1 % of NSCLC patients and in several other cancers such as cholangiocarcinoma, glioblastoma, or colorectal cancer. To date, crizotinib, an ALK/ROS1 inhibitor was approved and widely used for the treatment of R
Autor:
Markus Vähä-Koskela, Krister Wennerberg, Max Tomlinson, Prson Gautam, Tero Aittokallio, Channing J. Der, Adrienne D. Cox
Publikováno v:
Molecular Cancer Therapeutics. 18:A137-A137
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid tumors and one of the leading causes of cancer death world-wide. PDAC patients have the poorest prognosis with a median survival of less than 6 months and a 5-year survival r
Autor:
Ryohei Katayama, Makoto Nishio, Naoya Fujita, Yasushi Okuno, Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara
Publikováno v:
Molecular Cancer Therapeutics. 18:A125-A125
Introduction: ALK fusion gene is found in 3-5% of NSCLC patients. As the resultant ALK fusion protein constitutively activates ALK tyrosine kinase that causes tumorigenesis, ALK tyrosine kinase inhibitors have been developed for the treatment of ALK
Publikováno v:
Molecular Cancer Therapeutics. 18:C038-C038
Despite treatment, >50% of urothelial carcinomas (UCs) recur and progress to life-threatening, advanced UCs. The double combination gemcitabine+cisplatin (Gem+Cis) regimen is a standard treatment for advanced UCs. Gem is a DNA synthesis-inhibiting ag
Publikováno v:
Molecular Cancer Therapeutics. 18:C014-C014
Recent well-designed preclinical studies have demonstrated that KRAS mutations can activate the canonical NF-κB signaling pathway, which is a pivotal role in tumor progression. Therefore, inhibition of this KRAS-NF-κB axis would be a promising targ